Association between the use of lipid-lowering drugs and the risk of inflammatory bowel disease.

European journal of clinical investigation（2023）

引用 0|浏览0

暂无评分

摘要

Inhibition of the lipid-lowering drug-target NPC1L1 leads to an increased IBD risk, mainly in the UC population.

查看译文

关键词

Mendelian randomization,inflammatory bowel disease,lipid-lowering drug

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要